Search
Gilbert, AZ Paid Clinical Trials
A listing of 145 clinical trials in Gilbert, AZ actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 145
There are currently 145 clinical trials in Gilbert, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Banner MD Anderson Cancer Center, Mercy Gilbert Medical Center, GSK Investigational Site and Banner MD Anderson Cancer Center ( Site 0013). Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Recruiting
The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Research Site, Gilbert, Arizona
Conditions: Cardiovascular Disease
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Recruiting
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
Recruiting
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Arizona Arthritis and Rheumatology Associates - Gilbert - 3645 S Rome St, Gilbert, Arizona
Conditions: Sjögren's Syndrome
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Recruiting
Primary Objective:
To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state
Secondary Objectives:
1. To evaluate the effect of dazodalibep on patient-reported outcomes (PROs) in participants with SS.
2. To evaluate the effect of dazodalibep on measures of systemic activity, PROs, and salivary flow in participants with SS
3. To evaluate the safety and tolerability of multiple doses of dazodalibep in participants with SS
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Arizona Arthritis and Rheumatology Associates - Gilbert - 3645 S Rome St, Gilbert, Arizona
Conditions: Sjögren's Syndrome (SS)
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
Recruiting
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Recruiting
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Banner MD Anderson Cancer Center ( Site 0181), Gilbert, Arizona
Conditions: Carcinoma, Non-Small-Cell Lung
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
Recruiting
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Lighthouse Psychiatry Scottsdale, Gilbert, Arizona
Conditions: Treatment Resistant Depression
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Recruiting
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: TG Therapeutics Investigational Trial Site, Gilbert, Arizona
Conditions: Relapsing Multiple Sclerosis, Multiple Sclerosis
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Recruiting
This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to BCG therapy and unwilling or unfit to undergo radical cystectomy.
After providing written informed consent (in presence of an Independent Witness, if applicable), patients will receive an induction therapy consisting o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Banner Health- MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Bladder Carcinoma in Situ (CIS)
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
Recruiting
The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea due to hyperinflation despite optimal medical treatment. The Apreo BREATHE Airway Scaffold is a permanent implant designed to tent open native airways. The study will include up to 250 participants at up to 25 study centers located in the United States and Europe. Study su... Read More
Gender:
ALL
Ages:
Between 40 years and 84 years
Trial Updated:
07/29/2025
Locations: Banner Health, Gilbert, Arizona
Conditions: COPD, Emphysema
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Recruiting
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant i... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Gilbert Neurology /ID# 260179, Gilbert, Arizona
Conditions: Migraine
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Recruiting
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed.
Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
07/29/2025
Locations: Arizona Arthritis & Rheumatology Research, PLLC /ID# 252820, Gilbert, Arizona
Conditions: Systemic Lupus Erythematosus
1 - 12 of 145